Literature DB >> 21086081

Imatinib and the treatment of fibrosis: recent trials and tribulations.

Jessica Gordon1, Robert Spiera.   

Abstract

Imatinib mesylate has become a therapy of interest for the treatment of systemic sclerosis because of its ability to inhibit c-Abl and platelet-derived growth factor receptor, tyrosine kinases involved in profibrotic pathways. Preclinical data using in vitro and murine models of fibrosis have demonstrated the antifibrotic properties of imatinib. Imatinib is currently used widely in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other conditions, and a large amount of information is available regarding the safety of the medication in these patient populations. Whether imatinib will be tolerable or effective in the treatment of systemic sclerosis is the subject of several investigations. The aim of this review is to summarize this body of research to date.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21086081     DOI： 10.1007/s11926-010-0146-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  45 in total

Review 1.  Smad transcription factors.

Authors:  Joan Massagué; Joan Seoane; David Wotton
Journal:  Genes Dev       Date:  2005-12-01       Impact factor: 11.361

2.  Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Authors:  Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter
Journal:  N Engl J Med       Date:  2006-05-11       Impact factor: 91.245

3.  Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts.

Authors:  S A Jimenez; S Gaidarova; B Saitta; N Sandorfi; D J Herrich; J C Rosenbloom; U Kucich; W R Abrams; J Rosenbloom
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

6.  Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.

Authors:  Masaru Hatano; Atsushi Yao; Taro Shiga; Koichiro Kinugawa; Yasunobu Hirata; Ryozo Nagai
Journal:  Int Heart J       Date:  2010-07       Impact factor: 1.862

Review 7.  Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.

Authors:  Joel Rosenbloom; Susan V Castro; Sergio A Jimenez
Journal:  Ann Intern Med       Date:  2010-02-02       Impact factor: 25.391

8.  Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model.

Authors:  Minglun Li; Amir Abdollahi; Hermann-Josef Gröne; Kenneth E Lipson; Claus Belka; Peter E Huber
Journal:  Radiat Oncol       Date:  2009-12-21       Impact factor: 3.481

9.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Authors:  Attilio Olivieri; Franco Locatelli; Marco Zecca; Adele Sanna; Michele Cimminiello; Roberto Raimondi; Guido Gini; Nicola Mordini; Adriana Balduzzi; Pietro Leoni; Armando Gabrielli; Andrea Bacigalupo
Journal:  Blood       Date:  2009-04-29       Impact factor: 22.113

10.  Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis.

Authors:  Shinong Wang; Mark C Wilkes; Edward B Leof; Raimund Hirschberg
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-21
View more
  13 in total

1.  Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Authors:  Emily A Rosenthal; Pei-Shu Ho; Galen O Joe; Sandra A Mitchell; Susan Booher; Steven Z Pavletic; Kristin Baird; Edward W Cowen; Leora E Comis
Journal:  Support Care Cancer       Date:  2019-12-06       Impact factor: 3.603

2.  The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.

Authors:  Andreea M Bujor; Yoshihide Asano; Paul Haines; Robert Lafyatis; Maria Trojanowska
Journal:  Arthritis Rheum       Date:  2011-06

3.  Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Authors:  Kristin Baird; Leora E Comis; Galen O Joe; Seth M Steinberg; Fran T Hakim; Jeremy J Rose; Sandra A Mitchell; Steven Z Pavletic; William D Figg; Lawrence Yao; Kathleen C Flanders; Naoko Takebe; Stefanie Sarantopoulos; Susan Booher; Edward W Cowen
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

4.  The Role of TGF-β Receptors in Fibrosis.

Authors:  Sashidhar Nakerakanti; Maria Trojanowska
Journal:  Open Rheumatol J       Date:  2012-06-15

5.  Aberrant repair and fibrosis development in skeletal muscle.

Authors:  Christopher J Mann; Eusebio Perdiguero; Antonio L Serrano; Yacine Kharraz; Susana Aguilar; Patrizia Pessina; Pura Muñoz-Cánoves
Journal:  Skelet Muscle       Date:  2011-05-04       Impact factor: 4.912

6.  Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.

Authors:  Jessica Gordon; Robert Spiera
Journal:  Int J Rheumatol       Date:  2011-10-13

Review 7.  Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.

Authors:  Jacopo Olivieri; Sabrina Coluzzi; Imma Attolico; Attilio Olivieri
Journal:  ScientificWorldJournal       Date:  2011-10-25

8.  Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.

Authors:  Dominik Bettenworth; Florian Rieder
Journal:  Fibrogenesis Tissue Repair       Date:  2014-03-29

9.  RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis.

Authors:  Tong Liu; Jian Zhang; Jing Zhang; Xin Mu; Hui Su; Xiaoding Hu; Wenli Liu; Enbing Zhao; Weimin Li
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.

Authors:  Vishalakshi Viswanath; Meghana M Phiske; Vinay V Gopalani
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.